Pharmaceutical stocks faced pressure after US President Trump unveiled a phased tariff plan for imported generic medicines. This plan introduces steep duties on generic drugs after a two-year tariff-free window. Indian drugmakers are reassessing supply chains and investment plans due to potential future impacts. Companies without US manufacturing presence may face significantly altered economics. The announcement shifts focus to encouraging domestic production within the United States.